A vaccine jointly developed by Pfizer and BioNTech was 90 per cent effective in preventing Covid-19 infections in ongoing Phase 3 trials, the companies announced Monday.
“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent Covid-19," Pfizer chairman and CEO Albert Bourla said in a statement.
Based on supply projections, the companies said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021.